One of the difficulties in studying this disease is that the recurrence rate for cryptogenic stroke is relatively low, so to find a significant difference in treatment strategies, one needs to follow patients for a long period or enroll huge numbers, both of which are difficult and expensive. In this issue of the Journal, The foramen ovale persists as a normal variant in 20% to 30% of the adult population (2). PFO is more often found in adults <60 years of age with cryptogenic stroke than in the normal population: upward of 40% (3). The mechanism of stroke in these patients is thought to be right-to-left embolization of small venous thrombi or thrombus formation within the PFO itself. It is not known why the vast majority of people with PFO will never have embolic events, yet there exists a small subset of patients with PFO who have strokes and then are at higher risk for recurrent events. The recurrence risk for cryptogenic stroke in some studies has been as high as 3% to 5% per year (4). However, in the current meta-analysis, the annual recurrence rate in the medically treated group was only about 1%. Even with that low event rate, PFO closure halved the event rate. One explanation for the lower than expected event rate in the medical arm is that many patients thought to be at "high risk"
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were undoubtedly siphoned away and treated with PFO closure outside the trials. An event rate of 1% per year is a relatively low recurrence rate compared with other stroke mechanisms; nevertheless, given the young age at which these events occur, with a potentially long exposure period for subsequent events, that risk may be more substantial than it first Thrombogenics, WebMD Global, Wyeth, and Yamanouchi; and financial support for research projects from AstraZeneca and GlaxoSmithKline.
The current meta-analysis calculated the number needed to treat (NNT) at 67 to prevent 1 stroke over 2.5 years, which really is too short a horizon to consider for this disease. be given the autonomy to make the choice.
